IN8bio Inc Ordinary Shares INAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INAB is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $1.02
- Day Range
- $1.02–1.05
- 52-Week Range
- $0.65–3.48
- Bid/Ask
- $1.03 / $1.12
- Market Cap
- $45.45 Mil
- Volume/Avg
- 37,495 / 342,522
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 34
- Website
- https://www.in8bio.com
Valuation
|
Metric
|
INAB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.52 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
INAB
|
|---|---|
Quick Ratio | 3.95 |
Current Ratio | 4.57 |
Interest Coverage | −216.44 |
Quick Ratio
INAB
Profitability
|
Metric
|
INAB
|
|---|---|
Return on Assets (Normalized) | −86.99% |
Return on Equity (Normalized) | −123.24% |
Return on Invested Capital (Normalized) | −97.15% |
Return on Assets
INAB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dzsxnqdlm | Wlzf | $586.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xkvlznr | Vwpwbl | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xwnrskzmv | Vblnqw | $108.2 Bil | |
MRNA
| Moderna Inc | Rchcdhkp | Jrd | $50.9 Bil | |
ARGX
| argenx SE ADR | Nbngkljp | Cnhf | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Xtpjcxtb | Yxjp | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Svqvqql | Ttlcy | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mvmwxxmn | Czkhvqr | $14.6 Bil | |
INCY
| Incyte Corp | Xyppcwhm | Lmxlzhg | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fdfkgnqytj | Ptydg | $12.3 Bil |